Capstone Investment Advisors
SNDX icon

Capstone Investment Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Capstone Investment Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,895
Closed -$235K – 2527
2023
Q4 		$235K Buy
+10,895
New +$167K ﹤0.01% 1709

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Capstone Investment Advisors's SNDX Position: Q1 2024 in Review

Capstone Investment Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q1 2024, closing a stake of 10,895 shares — an estimated $235K sold.

Capstone Investment Advisors first reported a position in SNDX in Q4 2023 and held it in 1 quarter. The position peaked at $235K in Q4 2023. 189 funds tracked by Wall St. Rank hold SNDX as of Q1 2024.

  • Capstone Investment Advisors reported no remaining Syndax Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 10,895 Syndax Pharmaceuticals shares in Q1 2024, an estimated $235K.
  • Capstone Investment Advisors first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Capstone Investment Advisors's Syndax Pharmaceuticals position peaked at $235K in Q4 2023.
  • 189 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2024.

Based on Capstone Investment Advisors's 13F filing for Q1 2024, filed 1 May 2024.